Platform Validation & Partner Programs
Various (Oncology focus implied)
Pre-clinicalActive
Key Facts
About ImmuneBridge
ImmuneBridge is a Boston-based biotech founded in 2019, focused on revolutionizing cell therapy development through an integrated platform of ML-driven screening and scalable manufacturing. The company utilizes young, healthy umbilical cord blood units from public banks as a diverse and high-quality starting material to produce various immune cell types, including HSCs, NK cells, and T cells. By addressing universal pain points like high cost and poor manufacturability, ImmuneBridge is positioning itself as an enabling platform for partners in academia and industry. The company is currently in a pre-clinical, platform-validation stage, building partnerships to advance novel therapies toward the clinic.
View full company profile